Norda (NORD) Stock Overview

A biotechnology company, engages in the cancer diagnostic activities. More details

NORD fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	0/6
Past Performance	2/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 72.2% below our estimate of its fair value

Earnings grew by 304% over the past year

Risk Analysis

Earnings have declined by 15.7% per year over past 5 years

Shares are highly illiquid

Does not have a meaningful market cap (NOK416M)

Large one-off items impacting financial results

NORD Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Norda ASA Competitors

Price History & Performance

Summary of share price highs, lows and changes for Norda
Historical stock prices
Current Share Price	NOK 81.00
52 Week High	NOK 0
52 Week Low	NOK 0
Beta	0.085
1 Month Change	1.12%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	97.56%
5 Year Change	305.00%
Change since IPO	-99.18%

Recent updates

Shareholder Returns

	NORD	NO Biotechs	NO Market
7D	0%	1.2%	-1.5%
1Y	n/a	-15.0%	9.3%

Return vs Industry: Insufficient data to determine how NORD performed against the Norwegian Biotechs industry.

Return vs Market: Insufficient data to determine how NORD performed against the Norwegian Market.

Price Volatility

Is NORD's price volatile compared to industry and market?
NORD volatility
NORD Average Weekly Movement	n/a
Biotechs Industry Average Movement	8.7%
Market Average Movement	4.8%
10% most volatile stocks in NO Market	11.7%
10% least volatile stocks in NO Market	2.5%

Stable Share Price: NORD's share price has been volatile over the past 3 months compared to the Norwegian market.

Volatility Over Time: Insufficient data to determine NORD's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2002	n/a	Hilde Leinaas	www.nordasa.no

Norda ASA, a biotechnology company, engages in the cancer diagnostic activities. The company is involved in the research and development of Genefec, a diagnostic screening test for colorectal cancer. It also invests and trades in securities, real estates, and other assets.

Norda ASA Fundamentals Summary

How do Norda's earnings and revenue compare to its market cap?
NORD fundamental statistics
Market cap	NOK 415.67m
Earnings (TTM)	NOK 125.95m
Revenue (TTM)	NOK 371.86m

3.3x

P/E Ratio

1.1x

P/S Ratio

Is NORD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NORD income statement (TTM)
Revenue	NOK 371.86m
Cost of Revenue	NOK 0
Gross Profit	NOK 371.86m
Other Expenses	NOK 245.91m
Earnings	NOK 125.95m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	24.54
Gross Margin	100.00%
Net Profit Margin	33.87%
Debt/Equity Ratio	162.7%

How did NORD perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/09/06 20:39
End of Day Share Price	2025/08/22 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Norda ASA is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Espen Jørgensen	DNB Carnegie
John Savin	Edison Investment Research
Arvydas Noreika	Norne Securities AS

Norda ASAOTCNO:NORD Stock Report